Insulin Degludec / Insulin Aspart

New Delhi: In the first month of current year (CY) 2025, the Indian Pharmaceutical market reported a value growth of 8.7 per cent, driven by new introductions and price growth of existing therapies. The domestic market has shown signs of recovery, with value growth improving from 7.7 per cent in December, up from 9.9 per cent earlier. However, January's growth remains below the 9.5 per cent recorded in the year ago period. As per the market analysis share by a research firm` Pharmarack, “during the period all the therapies showing a positive value growth and majority therapies have shown positive unit growth compounded with the seasonal demand therapies which have shown encouraging performance.” The domestic market sales for January stood at ₹19,238 crore, reflecting a value growth of 8.7 per cent while a 2.4 per cent hike on the unit growth figures. Of the major therapy segments, cardiac sales went up by 10.2 per cent to ₹2,686 crore, gastro intestinal by 10.9 per cent to ₹2,218 crore, while despite reporting a contraction of 1.2 per cent in its volume the anti-diabetics generated ₹1,773 crore with a value growth of 6.9 per cent. Among the companies, Sun Pharma retained its top spot with total sales of ₹1,645 crore with a value growth of 13.7 per cent followed by Abbott and Mankind who generated ₹1,139 crore and ₹1,040 crore respectively. During the month, the companies who experienced maximum value growth includes Torrent Pharma (15.7 per cent), Eris (13.7 per cent), Intas (13.2 per cent) etc. According to the monthly assessment, UK-based GSK's antibiotic 'Augmentin' and USV's anti-diabetic drug 'Glycomet GP' topped the sales chart, with net sales of ₹73 crore and ₹68 crore, respectively with both undergoing a value growth of 0.7 per cent. In the last twelve month period till Jan 2025, the two drugs have maintained their dominance in the Indian market with net sales of ₹825 crore and ₹797 crore respectively. The brands which experienced the maximum value growth in January includes Ryzodeg (32.6 per cent) and Udiliv (25.5 per cent) of Abbott and Becosules (28.7 per cent) of Pfizer. By Online Bureau ,

On February 5, Novo Nordisk officially released its annual report for 2024, revealing a remarkable revenue of 29.04 billion Danish kroner (approximately $42.13 billion), representing a 25% increase year-on-year. The operating profit also surged to 12.83 billion Danish kroner (around $18.62 billion), reflecting a 25% growth, while net profit reached 10.10 billion Danish kroner (about $14.65 billion), up 21%. Notably, Novo Nordisk's profit margin (operating profit/sales) stands at an impressive 44.19%, far surpassing many American pharmaceutical giants.   Novo Nordisk operates primarily in two business segments: Diabetes and Obesity Care and Rare Diseases. The majority of its revenue comes from the Diabetes and Obesity Care segment, which generated 27.18 billion Danish kroner in sales for 2024, while the Rare Diseases segment contributed only 1.86 billion Danish kroner.   The GLP-1 class of drugs has emerged as Novo Nordisk's biggest revenue driver. Rybelsus (oral semaglutide) achieved sales of 23.30 billion Danish kroner (approximately $3.38 billion), while Ozempic (injectable semaglutide) brought in 120.34 billion Danish kroner (around $17.46 billion). The weight-loss version, Wegovy, also performed well with sales of 58.21 billion Danish kroner (about $8.44 billion). The total sales for semaglutide reached $29.28 billion, showcasing its strong performance, although it has not yet dethroned Keytruda as the new king of drugs. In addition to semaglutide, Novo Nordisk's GLP-1 offerings include the previous generation liraglutide, with Victoza (liraglutide for diabetes) and Saxenda (liraglutide for weight loss) generating 5.48 billion Danish kroner (approximately $795 million) and 6.94 billion Danish kroner (around $1.01 billion), respectively.   Insulin remains Novo Nordisk's second-largest revenue generator, with total sales of 55.37 billion Danish kroner (approximately $8.03 billion) in 2024, driven by the success of degludec insulin, which saw a 15.3% increase in sales compared to the previous year. The three long-acting insulins—Tresiba (degludec), Xultophy (degludec/liraglutide), and Levemir (detemir)—achieved sales of 9.91 billion, 4.67 billion, and 4.50 billion Danish kroner, respectively. The two premixed insulins, Ryzodeg (degludec/aspart) and NovoMix (premixed aspart), generated revenues of 4.93 billion and 5.86 billion Danish kroner, respectively, with the former showing growth while the latter declined. Rapid-acting insulins, including Fiasp (ultra-rapid aspart) and NovoRapid (aspart), collectively sold 18.52 billion Danish kroner, an increase of approximately 2.6 billion compared to the previous year. Additionally, Novo Nordisk continues to sell second-generation human insulin, which generated 6.97 billion Danish kroner, although this segment saw a year-on-year decline.   In the Rare Diseases segment, Novo Nordisk's product pipeline primarily includes clotting factors and growth hormones, with total sales of only 1.86 billion Danish kroner, representing a small portion of overall revenue.   Unlike other major international pharmaceutical companies, Novo Nordisk has not pursued large-scale acquisitions and maintains a research and development investment intensity of around 15%. However, the company's sustained high revenue growth demonstrates its efficiency in product development. This efficiency can be attributed to four key factors: a strong focus on diabetes, extensive knowledge accumulation over a century, a commitment to user experience, maximizing market value from existing products, and the development of platform technologies. With advanced fatty acid acylation technology, peptide oral delivery technology, and yeast fermentation technology, Novo Nordisk is well-positioned to maintain its competitive edge in the market.